IDT Australia (ASX: $IDT) secures new contract with Sanofi Australia

IDT Australia Limited (ASX: $IDT) has secured a follow-on contract with Sanofi Australia worth between $2.5 million and $4 million for the preclinical formulation, development and manufacture of Sanofi's messenger RNA (mRNA) technology for its translational clinical program.

Executive Commentary

The follow-on contract with Sanofi Australia is a testament to IDT's expertise in pharmaceutical manufacturing and development. This contract further solidifies our position as a trusted partner for high potency and high containment pharmaceutical products. We are committed to delivering exceptional services to Sanofi and look forward to contributing to the success of their translational clinical program.

Summary

IDT Australia Limited (ASX: $IDT) has successfully secured a follow-on contract with Sanofi Australia, demonstrating its capabilities in pharmaceutical manufacturing and development. The contract, valued between $2.5 million and $4 million, is for the preclinical formulation, development, and manufacture of Sanofi's messenger RNA (mRNA) technology. This achievement reflects IDT's commitment to providing full-scale services for new drug development and scale-up, as well as commercial active drug manufacture. The company's extensive experience and cGMP compliant facilities position it as a reliable partner for local and international clients. Looking ahead, IDT aims to continue delivering exceptional services and contributing to the success of its clients' clinical programs.